Status: Not yet recruiting

A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers

NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, double-blind, placebo-controlled, dose escalation phase 1 clinical trial to evaluate the safety, tolerability and PK/PD characteristics of NTQ5082 capsules orally administered in healthy subjects in single and multiple doses.

Participants needed: 82

Trial details

Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Nanjing Chia-tai Tianqing PharmaceuticalUpdated: Aug 19, 2024Locations: 1

Eligibility criteria

Healthy male or female, ≥18 years and ≤45 years in age. [+3]

Participants who have participated in any other drug clinical trials and used th... [+24]

Status: Not yet recruiting

Effect of Food of NTQ5082 in Healthy Subjects

NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, open label, two sequence, two period, double crossover-design phase 1 clinical trial to evaluate the food effect on PK after a single oral administration of NTQ5082 capsules and the safety and tolerability of single oral administration of NTQ5082 capsules on an empty stomach (i.e, fasting) as well as after a meal (i.e. fed) in healthy subjects

Participants needed: 12